Connacht Asset Management LP Inhibrx, Inc. Transaction History

Connacht Asset Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $38,329 - $62,873	-2,260 Reduced 19.77%	9,173 $238,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $13,099 - $19,269	-710 Reduced 5.85%	11,433 $215,000
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $16,325 - $26,963	-809 Reduced 6.25%	12,143 $299,000
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $18,006 - $38,455	-1,555 Reduced 10.72%	12,952 $232,000
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $18,283 - $54,207	2,146 Added 17.36%	14,507 $165,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $104,740 - $227,385	5,266 Added 74.22%	12,361 $275,000
Q4 2021 Feb 11, 2022	BUY	$26.75 - $46.02 $189,791 - $326,511	7,095 New	7,095 $310,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Connacht Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Connacht Asset Management LP with notifications on news.